Migraine

Defining and refining 5-HT receptor targets for migraine. By - Andrew Charles

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. By - Pro...

Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults. ... Inclusion and exclusion criteria of each study were reviewed. Headaches were categorized as episodic ( < 15 headaches per month) or chronic ( 15 headaches per

PLoS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world.

J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2011-302124. Autonomic. Short report. Headache in three new cases of Harlequin syndrome with accompanying pharmacological comparison with migraine. ... the flushing occurred, whereas the second patient,

Botulinum toxin A is US Food and Drug Administration approved for prophylactic treatment for chronic migraines.|To assess botulinum toxin A for the prophylactic treatment of headaches in adults.|A search of MEDLINE, EMBASE, bibliographies of published systematic reviews, and the Cochrane trial registries between 1966 and March 15, 2012. Inclusion and exclusion criteria of each study were reviewed. Headaches were categorized as episodic (<15 headaches per month) or chronic (15 headaches per month) migraine and episodic or chronic daily or tension headaches.|Randomized controlled trials comparing botulinum toxin A with placebo or other interventions for headaches among adults.|Data were abstracted and quality assessed independently by 2 reviewers. Outcomes were pooled using a random-effects model.|Pooled analyses suggested that botulinum toxin A was associated with fewer headaches per month among patients with chronic daily headaches (1115 patients, -2.06 headaches per month; 95% CI,

The aim of this study was to report a single-centre experience of flunarizine in childhood migraine with focus on safety and efficacy.|We conducted a retrospective observational audit of 72 individuals (40 male, 32 female; mean age 13y; age range 1y 6mo-17y) at a tertiary paediatric neurology unit between 1998 and 2009. Children were included if they had a diagnosis of migraine and at least one follow-up assessment and a minimum of 3 months' treatment with flunarizine.|Of 102 individuals identified, 30 were excluded for the following reasons: no outcome data (n=13), non-migraineurs (n=9), missing records (n=4), or inadequate treatment duration (n=4). Of the final cohort (72 individuals), 44 had migraine without aura, 15 had migraine with aura or childhood migraine equivalents, eight had sporadic hemiplegic migraine, and five had familial hemiplegic migraine. The median age was 13 years (1y 6mo-17y) and median duration of migraine was 48 months. Starting dose was 5mg. Other doses used

22142366 2012 02 13 2012 03 27 1469-8749 54 3 Mar Dev Med Child Neurol 204-5 10.1111/j.1469-8749.2011.04152.x Abu-Arafeh Ishaq I eng Comment Editorial 2011 12 05 England Dev Med Child Neurol 0006761 0012-1622 0 Vasodilator Agents 52468-60-7

22373969 2012 02 29 2012 04 23 1529-4242 129 3 Mar Plast. Reconstr. Surg. 629-30 Department of Plastic Surgery, Case Western Reserve University, Cleveland, Lyndhurst, Ohio, USA. bahman.guyuron@gmail.com Guyuron Bahman B eng Comment Journal Article

Chronic migraine (CM) and episodic migraine (EM) are part of the spectrum of migraine disorders, but they are distinct clinical entities. Population-based studies have shown that those with CM demonstrate higher individual and societal burden because they are significantly more disabled than those with EM and have greater impaired quality of life both inside and outside the home. Proper diagnosis of both conditions requires clearly defined clinical criteria. Diagnosis enables the initiation of appropriate treatments and risk-factor modification, which ultimately improve functional status and quality of life for persons with migraine. Recognizing that both disorders are on the spectrum of migraine, this review serves as a guide to define the disease state of CM as distinct from EM in terms of clinical, epidemiological, sociodemographic, and comorbidity profiles.

USER NAME:. PASSWORD:. Remember Me:. LOGIN INCORRECT:. Please double check that your user name and password are correct. CONNECTIVITY PROBLEM:. Try again later. Search. Clinical Information. The following guidelines have been produced by the

EFNS guideline on the drug treatment of migraine revised report of an EFNS task force.

CVS starts commonly in early childhood, and the vomit- ing symptoms may abate with the onset of classical migraine headaches during adolescence. ... ily prevalence of migraine in patients with CVS, effectiveness of antimigraine therapy ( 8 11).